pSivida (NSDQ:PSDV) touted 1-year follow-up data yesterday for the company’s Durasert 3-year treatment of posterior segment uveitis. The data, which was presented at the Association for Research in Vision and Ophthalmology annual meeting, is from pSivida’s 1st phase III trial.
The data showed that the 3-year uveitis implant significantly reduced the recurrence of posterior segment uveitis through 12 months – 27.6% of patients treated with Durasert had a recurrence, compared to 85.7% of patients in the sham group. In phakic patients, 33.3% in the Durasert group required a cataract surgery in the year-long follow-up, versus 4.8% of patients in the sham group.
Get the full story at our sister site, Drug Delivery Business News.